Skip to main content
Erschienen in: World Journal of Surgery 11/2017

12.06.2017 | Original Scientific Report

Prognostic Impact of Change in the Fibrinogen and Albumin Score During Preoperative Treatment in Esophageal Cancer Patients

verfasst von: Satoru Matsuda, Hiroya Takeuchi, Hirofumi Kawakubo, Kazumasa Fukuda, Rieko Nakamura, Koichi Suda, Norihito Wada, Yuko Kitagawa

Erschienen in: World Journal of Surgery | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

For resectable advanced esophageal cancer, a transthoracic esophagectomy following preoperative treatment is recognized as one of the standard treatments. Therefore, predictive markers which can be identified before surgery need to be established to identify patients with a poor prognosis.

Methods

We retrospectively reviewed 102 consecutive patients who underwent curative transthoracic esophagectomy following preoperative treatment in our institution between 2004 and 2013. Based on plasma fibrinogen and serum albumin levels, the pretreatment and preoperative fibrinogen and albumin score (FA score) were investigated and the prognostic significance of the FA score change was compared with RECIST.

Results

The patients were classified according to whether the FA score had remained unchanged or decreased (n = 77) or the FA score increased (n = 25). When the correlation between the response rate and change in the FA score was investigated, the response rate was significantly lower in the group with the increased FA score. In the survival analysis, patients in the increased FA score group exhibited a significantly worse recurrence-free survival (RFS) (P = 0.038). A multivariate analysis using the clinical stage and the change in the FA score as covariates revealed that a change in the FA score (HR 1.802; P = 0.047; 95% CI 1.008–3.221) was shown to be a significant independent predictive factor for RFS.

Conclusions

A change in the FA score was shown to be an independent prognostic factor for postoperative recurrence in esophageal cancer patients who have undergone transthoracic esophagectomy following preoperative treatment.
Literatur
1.
Zurück zum Zitat Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692CrossRefPubMed Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692CrossRefPubMed
2.
Zurück zum Zitat Matsuda S, Takeuchi H, Kawakubo H et al (2016) Current advancement in multidisciplinary treatment for resectable cStage II/III esophageal squamous cell carcinoma in Japan. Ann Thorac Cardiovasc Surg 20:275–283CrossRef Matsuda S, Takeuchi H, Kawakubo H et al (2016) Current advancement in multidisciplinary treatment for resectable cStage II/III esophageal squamous cell carcinoma in Japan. Ann Thorac Cardiovasc Surg 20:275–283CrossRef
3.
Zurück zum Zitat Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68–74CrossRefPubMed Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68–74CrossRefPubMed
4.
Zurück zum Zitat van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084CrossRefPubMed van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084CrossRefPubMed
5.
Zurück zum Zitat Takeuchi H, Miyata H, Gotoh M et al (2014) A risk model for esophagectomy using data of 5354 patients included in a Japanese Nationwide Web-Based Database. Ann Surg 260:259–266CrossRefPubMed Takeuchi H, Miyata H, Gotoh M et al (2014) A risk model for esophagectomy using data of 5354 patients included in a Japanese Nationwide Web-Based Database. Ann Surg 260:259–266CrossRefPubMed
6.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
7.
Zurück zum Zitat Chun YS, Vauthey JN, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338–2344CrossRefPubMedPubMedCentral Chun YS, Vauthey JN, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338–2344CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Matsuda S, Takeuchi H, Kawakubo H et al (2015) Cumulative prognostic scores based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transthoracic esophagectomy: comparison with the Glasgow prognostic score. Ann Surg Oncol 22:302–310CrossRefPubMed Matsuda S, Takeuchi H, Kawakubo H et al (2015) Cumulative prognostic scores based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transthoracic esophagectomy: comparison with the Glasgow prognostic score. Ann Surg Oncol 22:302–310CrossRefPubMed
9.
Zurück zum Zitat Japanse Esophageal Society (2017) Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus 14:37–65CrossRef Japanse Esophageal Society (2017) Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus 14:37–65CrossRef
10.
Zurück zum Zitat Hara H, Tahara M, Daiko H et al (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104:1455–1460CrossRefPubMed Hara H, Tahara M, Daiko H et al (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104:1455–1460CrossRefPubMed
11.
Zurück zum Zitat Tennent GA, Brennan SO, Stangou AJ et al (2007) Human plasma fibrinogen is synthesized in the liver. Blood 109:1971–1974CrossRefPubMed Tennent GA, Brennan SO, Stangou AJ et al (2007) Human plasma fibrinogen is synthesized in the liver. Blood 109:1971–1974CrossRefPubMed
12.
13.
Zurück zum Zitat Kanda M, Tanaka C, Kobayashi D et al (2017) Proposal of the coagulation score as a predictor for short-term and long-term outcomes of patients with resectable gastric cancer. Ann Surg Oncol 24:502–509CrossRefPubMed Kanda M, Tanaka C, Kobayashi D et al (2017) Proposal of the coagulation score as a predictor for short-term and long-term outcomes of patients with resectable gastric cancer. Ann Surg Oncol 24:502–509CrossRefPubMed
14.
Zurück zum Zitat Holzinger D, Danilovic I, Seemann R et al (2016) Prognostic impact of pretreatment plasma fibrinogen in patients with locally advanced oral and oropharyngeal cancer. PLoS One 11:e0158697CrossRefPubMedPubMedCentral Holzinger D, Danilovic I, Seemann R et al (2016) Prognostic impact of pretreatment plasma fibrinogen in patients with locally advanced oral and oropharyngeal cancer. PLoS One 11:e0158697CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Perisanidis C, Psyrri A, Cohen EE et al (2015) Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev 41:960–970CrossRefPubMed Perisanidis C, Psyrri A, Cohen EE et al (2015) Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev 41:960–970CrossRefPubMed
16.
Zurück zum Zitat Palumbo JS, Kombrinck KW, Drew AF et al (2000) Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96:3302–3309PubMed Palumbo JS, Kombrinck KW, Drew AF et al (2000) Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96:3302–3309PubMed
17.
Zurück zum Zitat Palumbo JS, Talmage KE, Massari JV et al (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178–185CrossRefPubMed Palumbo JS, Talmage KE, Massari JV et al (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178–185CrossRefPubMed
18.
Zurück zum Zitat Simpson-Haidaris PJ, Rybarczyk B (2001) Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci 936:406–425CrossRefPubMed Simpson-Haidaris PJ, Rybarczyk B (2001) Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci 936:406–425CrossRefPubMed
19.
Zurück zum Zitat Camerer E, Qazi AA, Duong DN et al (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104:397–401CrossRefPubMed Camerer E, Qazi AA, Duong DN et al (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104:397–401CrossRefPubMed
20.
Zurück zum Zitat Takeuchi H, Ikeuchi S, Kitagawa Y et al (2007) Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol 22:2222–2227CrossRefPubMed Takeuchi H, Ikeuchi S, Kitagawa Y et al (2007) Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol 22:2222–2227CrossRefPubMed
21.
Zurück zum Zitat Matsuda S, Takeuchi H, Fukuda K et al (2014) Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment. Dis Esophagus 27:654–661CrossRefPubMed Matsuda S, Takeuchi H, Fukuda K et al (2014) Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment. Dis Esophagus 27:654–661CrossRefPubMed
Metadaten
Titel
Prognostic Impact of Change in the Fibrinogen and Albumin Score During Preoperative Treatment in Esophageal Cancer Patients
verfasst von
Satoru Matsuda
Hiroya Takeuchi
Hirofumi Kawakubo
Kazumasa Fukuda
Rieko Nakamura
Koichi Suda
Norihito Wada
Yuko Kitagawa
Publikationsdatum
12.06.2017
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 11/2017
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-4074-8

Weitere Artikel der Ausgabe 11/2017

World Journal of Surgery 11/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.